MedTrace Logo

The Role of Circulating Soluble CD74 in Acute Lung Injury

NCT02201446 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 139

Last updated 2017-02-17

Study results available
· View outcomes & findings →

Summary

Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome（ALI/ARDS） patients is unrevealing. The primary purpose of this study is to verify our hypothesis that soluble CD74 might be a potential novel ALI/ARDS biomarker.

Conditions

  • Acute Lung Injury
  • Acute Respiratory Distress Syndrome

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Zhaofan Xia, MD PhD · Department of Burn Sugery, Changhai Hospital

Eligibility

Min Age
16 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-11-30
Completion
2015-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02201446 on ClinicalTrials.gov